![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.
Acknowledgements
This work was financed by Fundação para a Ciência e a Tecnologia (FCT/MEC – Project UCIBIO UID/Multi/04378/2013) and co-financed by ERDF under PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). RV was supported by PD/BD/52211/2013, MC by SFRH/BD/87836/2012, PP by PD/BD/105734/2014 (FCT/MEC grants).
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2016.1265116.